Amazon Target Raised on Expectations and 4 Stock Analyses to Follow

Edwards Lifesciences Corp. (NYSE:EW): Current Price: $92.57

The company has been added to William Blair’s Current Better Values List due to expectations that the company is in the position to deliver product revenue growth with an averaging exceeding 15 percent and earnings growth with an average of 25 percent over the next three years. The firm keeps an Outperform rating on the name.

Capture

Start 2013 better than ever by saving time and making money with your Limited Time Offer for our highly-acclaimed Stock Picker Newsletter. Get our fresh Feature Stock Pick now!

Regal Beloit Corporation (NYSE:RBC): Current Price: $72.77

Regal-Beloit ┬áhas been added to William Blair’s Current Better Values List due to expecations that the company will see benefits from the growing global emphasis on improving energy efficiency. The firm has reiterated its Outperform rating on the stock.

Capture

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

Weyerhaeuser Co. (NYSE:WY): Current Price: $29.68

The company’s estimates and price target has been increased by Citigroup, and the firm continues to name the stock as a top pick. Citi predicts that Weyerhaeuser’s upward earnings revision cycle will continue through 2013.

Capture

Start 2013 better than ever by saving time and making money with your Limited Time Offer for our highly-acclaimed Stock Picker Newsletter. Get our fresh Feature Stock Pick now!

Amazon.com Inc. (NASDAQ:AMZN): Current Price: $268.76

Benchmark Co. decided to increase its price target for Amazon.com shares due to expectations that growing digital sales and strong 3P sales have the potential to drive better than expected operating leverage during Q4 and 2013. The firm has decided to maintain its Buy rating on the stock.

Capture

Medicines Co. (NASDAQ:MDCO): Current Price: $28.45

Leerink has decided to increase its price target for The Medicines Co. following its announcement of positive Phase 3 results of the PHOENIX trial of Cangrelor. The firm predicts that it is possible for Cangrelor to address a $200 million U.S. market opportunity, and it keeps its Outperform rating on the stock.

Capture

Investing Insights: Should Vodafone Take This Deal?